Cutting Balloon Versus Conventional Balloon Angioplasty for the Treatment of Coronary Artery Disease

Similar documents
Rotational Atherectomy for the Treatment of In-Stent Restenosis

Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up

Evolu'on of Balloon Angioplasty From POBA to newer technologies NCVH May 26, 2015

ORIGINAL ARTICLES: Morphology and Location of Restenosis Following Bare Metal Coronary Stenting

Review of Intracoronary Radiation for In-Stent Restenosis

European Heart Journal (1999) 20, Article No. euhj , available online at on

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI

MEDICAL POLICY No R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA - A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES -

Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)

Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam

The Bioresorbable Vascular Stent Dr Albert Ko

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.

NOVOSTE BETA-CATH SYSTEM

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III

Majestic Trial 12 Month Results

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Editorial. Adult Cardiology - Meta-analysis

OCT ASSESSMENT OF CUTTING BALLOON ANGIOPLASTY FOR IN-STENT RESTENOSIS

Status of Drug-Eluting Coronary Stents

California Health and Safety Code, Section

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,

Imaging of Thoracic Endovascular Stent-Grafts

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?

Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases

Cilostazol versus Clopidogrel after Coronary Stenting

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

STONY BROOK UNIVERSITY HOSPITAL VASCULAR CENTER CREDENTIALING POLICY

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program

SAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to Reference Code: GDMECR0061PDB. Publication Date: May 2014

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

AND SYLLABUS FOR INTERVENTIONAL CARDIOLOGY SUBSPECIALITY TRAINING IN EUROPE

CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD

SeQuent Please balloon catheter for in-stent coronary restenosis. NICE medical technology guidance 1. Issue date: December 2010

INTRODUCTION. Key Words:

LEADERS: 5-Year Follow-up

PATIENT INFORMATION BOOKLET

Early And Late Outcome For Single Versus Double Stenting For Bifurcational Coronary Artery Lesions

INTERVENTION IN OSTIAL CORONARY LESIONS:

Clinical Programs. Medtronic Coronary Stent Systems. driver BMS

Antonio Colombo MD on behalf of the SECURITY Investigators

Fundación Favaloro. Fundación Favaloro

Perioperative Cardiac Evaluation

Coronary Stents. What is a Coronary Artery stent?

Angioplasty and Stent Education Guide

Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo Lesions: The Pivotal TAXUS ATLAS Trial

Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

ESC PCI Guidelines: / Sigmund Silber et al. 1

TAXUS Express 2. Paclitaxel-Eluting Coronary Stent System. Patient Information Guide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C Form 10-K

European Cardiology. Volume 6 Issue 4 Extract. Svelte Acrobat Stent-On- A-Wire Coronary Stent System. J Ribamar Costa Jr and Alexandre Abizaid

Medical publications - Open Vs Closed Cell Stents

έΰζβν αππ έκυ,νσϊίία κν1γν πλδζέκυνβί1γ π ηία δεόμνκαλ δκζόΰκμ, θν δ υγυθ άμνγνκαλ /εάμ ΚζδθδεάμΝ υλωεζδθδεάμν

Popliteal artery: to stent or not to stent?

Renovascular Hypertension

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial

Rounds CARDIOLOGYTM. Percutaneous coronary intervention in the management of coronary artery disease.

Clinical Results of Unprotected Left Main Coronary Stenting

Payment policies are potentially a strong driver of diffusion of

Coronary in-stent restenosis predictors, treatment and prevention

University of Missouri Kansas City School of Medicine and the Mid America Heart Institute of Saint Luke s Hospital

TAXUS Express2 Paclitaxel-Eluting Coronary Stent System TAXUS Liberté Paclitaxel-Eluting Coronary Stent System. A Patient s Guide

SUTTER MEDICAL CENTER, SACRAMENTO Department of Cardiovascular Disease Cardiology - Delineation of Privileges

CARDIAC RISKS OF NON CARDIAC SURGERY

R EFERENCES. Summary and conclusions

Intracoronary stenting is an established treatment

Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April Reference: NHSCB/A09/PS/b

Validation of a Risk Score for Target Vessel Revascularization after Coronary Stent Implantation

GRAFTMASTER RX Coronary Stent Graft System PPL (2/1/13)

Clinical Study Synopsis

Coronary Stents. Artery Disease Review of Firs00t 1. Coronary Stents in the Management of

OPINION OPtical frequency domain imaging vs. INtravascular ultrasound in percutaneous coronary InterventiON

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

2014 Procedural Reimbursement Guide Select Percutaneous Coronary Interventions

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona

2015 European Coronary Stent New Product Innovation Award

Carotid Artery Stenting? Comparison of the outcome of octogenarian patients according to the stent type. Data from a multicentre registry

Understanding Coronary Artery Disease, Cardiac Catheterization, and Treatment Options. A Guide for Patients

Ischemia and Infarction

OCT STEMI: OCT guidance during stent implantation

Review Article CORONARY STENTS - PAST, PRESENT AND FUTURE.

First Experience With Drug-Eluting Balloons in Infrapopliteal Arteries

Wingspan Stent System with Gateway PTA Balloon Catheter

Ultrasound in Vascular Surgery. Torbjørn Dahl

Intravascular Diagnostic Procedures and Imaging Techniques Versus Angiography Alone in Coronary Stenting: Future Research Needs

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

Cardiovascular disease has become a dominant cause of

FFR CT : Clinical studies

Everolimus Eluting Coronary Stent System. Patient Information Guide

High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: Angioscopic comparison with sirolimus-eluting stent

REPORTING STENT PLACEMENT FOR NONOCCLUSIVE VASCULAR DISEASE IN LOWER EXTREMITIES

Drug-Eluding Stents as an Alternative to Traditional Stenting in the Treatment of Coronary Artery Disease

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

INVESTIGATION OF METALLIC SURFACE AREA OF CORONARY STENTS

ST. DAVID S MEDICAL CENTER CARDIOLOGY - Special, Invasive, Diagnostic, or High-Risk Procedure Requirements

Transcription:

Cutting Balloon Versus Conventional Balloon Angioplasty for the Treatment of Coronary Artery Disease a report by Dr Remo Albiero Director, Cardiac Catheterisation Laboratory, Clinica San Rocco, Brescia Dr Remo Albiero is Director of the Cardiac Catheterisation Laboratory at the Clinica San Rocco (Gruppo San Donato) in Brescia, Italy. He was previously Senior Associate of the Catheterisation Laboratory at EMO Centro Cuore Columbus in Milan, Italy. Since 1989 he has had 124 abstracts presented at the American College of Cardiology (ACC)/European Society of Cardiology (ESC)/American Heart Association (AHA) congresses 21 as first author. He also has 68 English language publications, with 2 of these as first author. He has been co-author on numerous journal articles. Dr Albiero graduated in medicine and surgery from the University of Verona in 1987, and a obtained diploma in cardiology from the same university in 1991. The cutting balloon (CB) 1 is a special balloon catheter with three or four atherotomes (microsurgical blades) bonded longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. With the cutting balloon, the increase in the vessel lumen diameter is obtained in a more controlled fashion and with a lower balloon inflation pressure than conventional percutaneous transluminal coronary angioplasty () this controlled dilatation could reduce the extent of vessel wall injury and the incidence of restenosis. The Global trial, 2 a multicentre, randomised trial on 1,238 patients, tested the hypothesis that surgical dilatation using the CB (617 patients) could result in less arterial trauma, fewer dissections and less frequent restenosis than conventional (621 patients). The lesion selected in this study (simple type A/B1 lesions) were treated by a single cutting balloon inflation, with a balloon artery ratio of 1.1:1. The controlled dilatation of the cutting balloon did not reduce the rate of angiographic restenosis compared with conventional (CB 31.4%, compared with 3.4%, p=.75). Five coronary perforations occurred only in the CB arm (.8% compared with %, p=.3). The results of the Global trial indicate that CB angioplasty in simple lesions is not superior to conventional for the prevention of restenosis and should probably be reserved for more complex lesions in which the controlled dilatation of the CB could provide better acute and mid-term results compared with conventional. In fact, this device is mainly used to treat in-stent restenosis (ISR), ostial lesions, bifurcation lesions and smaller vessels and to expand resistant fibrocalcified plaques not dilated by high pressure conventional balloons. subgroup of patients with diffuse and/or severe ISR. 3,5,7 1 Numerous small retrospective studies have shown the benefits of the CB for the prevention of the recurrence of ISR compared with conventional. 11,12 These studies were followed by small pilot randomised studies that also showed a clinical benefit associated with the use of a CB. 13 The author s prior observation 14 demonstrated a greater capacity of cutting balloon angioplasty (CBA) to extrude a fibrous residual neo-intimal plaque out of the stent struts than conventional. The microblades of the cutting balloon were able to surgically incise the restenotic plaques up to the metallic stent cage these incisions probably facilitated the maximum extrusion of the neo-intimal plaque. This hypothesis was confirmed by an intravascular ultrasound (IVUS) study 11 that showed a larger luminal area acute gain after CBA (2.5 ±.8mm 2 ) than after conventional (1.8 ± 1.mm 2 ), which translated into a lower restenosis rate at 5.4-month follow-up (CBA 24%; 59%). Two large prospective, randomised, multicentre studies both failed to demonstrate an advantage of the CB over for the treatment of ISR: the Restenosis Cutting Balloon Evaluation Trial (RESCUT); and the Restenosis Reduction by Cutting Balloon Evaluation (REDUCE) II trial. The RESCUT trial 15 is a European study designed to assess the results of CB (n = 214) compared with conventional (n = 214) for the treatment of ISR. The study included lesions shorter than 25mm in native coronary arteries with all types of ISR patterns (focal, multifocal, diffuse and proliferative). 48 In-stent Restenosis With the rapid explosion in stent use, ISR has become a significant clinical problem. 3 Re-dilatation using a conventional balloon has been the most commonly used approach to treat ISR, 4 7 but with a high recurrent restenosis rate, especially in the This large multicentre randomised study differed from previous reports 11 14 in that the rates of clinical events (death, myocardial infarction (MI) and target lesion revascularisation (TLR)) were similar between the two groups (see Figure 1), as well as the rates of restenosis and its patterns (see Figure 2 and 3).

albiero_papextended.qxp 14/4/5 12:43 pm Page 49 Cutting Balloon Versus Conventional Balloon Angioplasty for the Treatment of CAD The CB demonstrated some practical advantages over conventional : revascularisation compared with conventional angioplasty (1.2% compared with 16.6%; p=.4).16 balloon slippage was less frequent in the CB group (6.5% compared with 25%, p<.1); and The use of CBs could not translate into clinical or angiographic benefits for patients with ISR treated with drug-eluting stents (DES), as a result of the procedural differences in the treatment of ISR using adjunctive brachytherapy compared with restenting using a DES. In the first case (before adjunctive brachytherapy), it is recommended to optimally treat ISR by conventional/cba or atherectomy, avoiding additional stenting to reduce the risk of late stent thrombosis. In the case of restenting with a DES, an optimal balloon pre-treatment of ISR is not necessary, nor is the use of a CB to avoid balloon slippage, because the operator can reduce the risk of vessel injury at the stent edges, even in the event of balloon slippage, by simply predilating the ISR lesion using an undersized non-compliant conventional balloon. there was a trend towards a lower need for additional stenting (CB 3.9% compared with 8.%, p=.7), mainly due to a lower frequency of residual stenosis more than 3% and type D F dissections. These advantages could be explained as follows: conventional balloons, particularly short balloons when positioned within in-stent restenotic lesions, tend to move forwards or backwards during inflation into larger segments with lower resistance, because the hyperplastic tissue has a smooth slippery surface. With a CB this problem is prevented by the blades, which anchor the balloon to the plaque during balloon inflation, reducing the risk of dissection at the stent margins. This fact could be important when there is the need to carefully control the boundaries of the injured segment, for example before coronary brachytherapy, as demonstrated in the Registry Novoste (RENO) where pre-treatment with CB before brachytherapy (performed using beta radiation) significantly reduced six-month target-vessel The second randomised multicentre trial to be discussed is the Japanese REDUCE II trial on 416 patients. The six-month result of this study (not yet published at the time of press) were not different between the two groups binary restenosis was 24% in the CB group compared with 22% in the arm and TLR was 2% in both arms.

Figure 1: RESCUT Cumulative MACE 2 1 Figure 2: RESCUT Restenosis at Seven-month Follow-up 35 p=ns 1.9 1.9 1.9 1.4 Death MI TLR 29.3 31.3 p=.82 17 15.8 compared with CB angioplasty and conventional. A total of 263 patients with a lesion in a small vessel (reference diameters less than 3mm) were randomly assigned to undergo GPBA (n=85), CBA (n=88), or conventional (n=9). The cumulative inflation time was more than 1 minutes in GPBA. Compared with conventional, GPBA resulted in a lower final residual diameter stenosis (27.3% compared with 34.2%, p=.1) and decreased the need for stent placement (8.% compared with 22.2%, p=.31). At follow-up, the restenosis rates were lower with GPBA (31.3%, p=.34) and CBA (32.9%, p=.59) than conventional (5.6%). Target lesion revascularisation was less frequently needed with GPBA (2.5%, p=.43) and CBA (2.%, p=.33) than conventional plain old balloon angioplasty (POBA) (37.6%). 18 28 21 14 7 Restenosis Figure 3: RESCUT Patterns of Restenosis Another retrospective study in small coronary arteries evaluated the clinical and angiographic benefits of stenting compared with CB angioplasty and conventional. A total of 327 lesions in small vessels (reference diameters less than 2.5mm by quantitative coronary angiography (QCA)) were analysed stenting (n=11), CB (n=87) and conventional (n=13). Angiographic restenosis was encountered in 43.9% of the stent, 31% of the CB and 46.5% of the conventional groups (p =.48). 8 4 22.6 21.4 p=ns 77.4 78.6 Major adverse coronary events (MACE; death, MI and TLR) at follow-up were significantly lower in the CB compared with other groups (CB, 2.3%; conventional, 37.3%; stent, 33.3%; p=.36). In conclusion, in small vessels less than 2.5mm, the CB procedure provided superior angiographic and clinical outcomes to stenting or conventional. 19 Focal <1mm Ostial or Bifurcation Lesions The CB may provide an advantage over conventional in complex lesions such as ostial or bifurcation lesions; however, a large retrospective study of 1,58 patients did not show a lower TLR in patients treated with the CB compared with conventional in ostial or bifurcation lesions. 17 Small Vessels Diffuse >1mm Before Stenting By favourably scoring the plaque prior to stent implantation, CBA may be preferable (compared with a conventional balloon) before stent placement. This hypothesis was evaluated in the REDUCE III study, a Japanese prospective, randomised multicentre trial on 52 patients. At six-month follow-up, restenosis rate was significantly lower in the CB group compared with conventional (1.7% compared with 17.1%, respectively, p=.58). Table 1 summarises the possible indications for use of the CB, instead of a conventional balloon, before implanting a DES. 5 Small vessel size represents a critical risk factor for an adverse outcome after both conventional and stenting. A recent study in small coronary arteries evaluated the clinical and angiographic benefits of gradual and prolonged balloon angioplasty (GPBA) using a perfusion balloon, to cause less arterial trauma, CB Complications and Drawbacks A trend for higher complication rates have been reported with the use of CB, including vessel perforation when using oversized balloons or when the CB is used outside the stent, 2,21 dissection, 22,23

Cutting Balloon Versus Conventional Balloon Angioplasty for the Treatment of CAD spasm and entrapment. 24 The co-existence of many, rather than a single, anatomical and procedural characteristics may increase the risk of vascular complications following CB angioplasty. The lesion eccentricity is probably the most important factor, followed by vessel calcification and a large balloon artery ratio. The appearance, at angiography, of an overdilated vessel after CBA should raise suspicion of an excessively deep cut of the device. 23 Finally, the cost of the CB is higher (US$1, compared with US$25 for conventional balloon). Conclusions Based on the available data, the CB can be used: to treat in-stent restenosis, due to some procedural advantages over conventional the microblades (atherotomes) prevent balloon slippage (melon-seeding), reducing the injury zone and edge dissection; to treat small vessels, although a gradual and prolonged CBA using a perfusion balloon could be equally effective in reducing restenosis; based on anecdotal data, to reduce plaque shift in ostial/bifurcation lesions; based on anecdotal data, to treat resistant Table1: Reasons to Use the Cutting Balloon Before Implantation of a DES Type of lesion Reason to use cutting balloon In-stent restenosis (ISR) Conventional balloon slips causing injury distally. CB scores the intimal hyperplasia which favours plaque extrusion through original stent struts, maximising lumen area before DES placement. Small vessel CB compressed the plaque, creating a larger lumen area for stent placement. Bifurcation CB reduces plaque shift, while direct stenting and POBA cause it. In highly fibrotic lesions, CB severs the fibrotic strands. In focal lesions, the 6mm long CB controls the injury zone. Ostial CB reduce plaque shift, while direct stenting and (side branch and aorta) POBA cause it. In highly fibrotic lesions, CB severs the fibrotic strands. In focal lesions, the 6mm long CB controls the injury zone. Resistant POBA and stenting do not resolve the stenosis. (hard plaque and calcium) Easier to use than rotational atherectomy. lesions, although rotational atherectomy is preferred (CB is difficult to deliver in moderate to severe calcified lesions); and before stenting using a bare-metal stent (REDUCE III). New Vascular Horizons PEOPLE. IDEAS. PASSION. Stroke Management Emboli Management Peripheral Intervention PRIMUS Peripheral Embolisation www.ev3.net THE ENDOVASCULAR COMPANY TM

References 1. Barath P, Fishbein M C, Vari S et al., : a novel approach to percutaneous angioplasty, Am. J. Cardiol. (1 November 1991);68(11): pp. 1,249 1,252. 2. Mauri L, Bonan R, Weiner B H et al., angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial, Am. J. Cardiol. (15 November 22);9(1): pp. 1,79 1,83. 3. Mintz G S, Hoffmann R, Mehran R et al., In-stent restenosis: the Washington Hospital Center experience, Am. J. Cardiol. (9 April 1998);81(7A):7E 13E. 4. Baim D S, Levine M J, Leon M B et al., Management of restenosis within the Palmaz-Schatz coronary stent (the U.S. multicenter experience. The U.S. Palmaz-Schatz Stent Investigators, Am. J. Cardiol. (1 February 1993);71(4): pp. 364 366. 5. Bauters C, Banos J L, Van Belle E et al., Six-month angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis, Circulation (3 February 1998);97(4): pp. 318 321. 6. Reimers B, Moussa I, Akiyama T et al., Long-term clinical follow-up after successful repeat percutaneous intervention for stent restenosis, J. Am. Coll. Cardiol. (July 1997);3(1): pp. 186 192. 7. Bossi I, Klersy C, Black A J et al., In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty, J. Am. Coll. Cardiol. (May 2);35(6): pp. 1,569 1,576. 8. Mehran R, Dangas G, Abizaid A S et al., Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome, Circulation (2 November 1999);1(18): pp. 1,872 1,878. 9. Kini A, Marmur J D, Dangas G et al., Angiographic patterns of in-stent restenosis and implications on subsequent revascularization, Catheter Cardiovasc. Interv. (Jan 2);49(1): pp. 23 29. 1. Eltchaninoff H, Koning R, Tron C et al., Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate, J. Am. Coll. Cardiol. (October 1998);32(4): pp. 98 984. 11. Muramatsu T, Tsukahara R, Ho M et al., Efficacy of cutting balloon angioplasty for in-stent restenosis: an intravascular ultrasound evaluation, J. Invasive Cardiol. (June 21);13(6): pp. 439 444. 12. Adamian M, Colombo A, Briguori C et al., angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty, J. Am. Coll. Cardiol. (September 21);38(3): pp. 672 679. 13. Montorsi P, Galli S, Fabbiocchi F et al., Randomized trial of conventional balloon angioplasty versus cutting balloon for in-stent restenosis. Acute and 24-hour angiographic and intravascular ultrasound changes and long-term follow-up, Ital. Heart J. (April 24);5(4): pp. 271 279. 14. Albiero R, Nishida T, Karvouni E et al., angioplasty for the treatment of in-stent restenosis, Catheter Cardiovasc. Interv. (August 2);5(4): pp. 452 459. 15. Albiero R, Silber S, Di Mario C et al., versus conventional balloon angioplasty for the treatment of instent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT), J. Am. Coll. Cardiol. (17 March 24);43(6): pp. 943 949. 16. Roguelov C, Eeckhout E, De Benedetti E et al., Clinical outcome following combination of cutting balloon angioplasty and coronary beta-radiation for in-stent restenosis: a report from the RENO registry, J. Invasive Cardiol. (December 23);15(12): pp. 76 79. 17. Bair et al., J. Am. Coll. Cardiol. (23);41:5A 18. Umeda H, Iwase M, Kanda H et al., Promising efficacy of primary gradual and prolonged balloon angioplasty in small coronary arteries: a randomized comparison with cutting balloon angioplasty and conventional balloon angioplasty, Am. Heart J. (January 24);147(1):E4. 19. Iijima R, Ikari Y, Wada M et al., angioplasty is superior to balloon angioplasty or stent implantation for small coronary artery disease, Coron. Artery Dis. (November 24);15(7): pp. 435 44. 2. Ako J, Honda Y, Fitzgerald P J, Impending coronary perforation after cutting balloon angioplasty, Heart (January 25);91(1):e8. 21. Quan V H, Stone J R, Couper G S et al., Coronary artery perforation by cutting balloon resulting in dissecting subepicardial hematoma and avulsion of the vasculature, Catheter Cardiovasc. Interv. (February 25);64(2): pp. 163 168. 22. Haridas K K, Vijayakumar M, Viveka K et al., Fracture of cutting balloon microsurgical blade inside coronary artery during angioplasty of tough restenotic lesion: a case report, Catheter Cardiovasc. Interv. (February 23);58(2): pp. 199 21. 23. Montorsi P, Galli S, Fabbiocchi F et al., Different types of coronary artery wall injury following cutting balloon angioplasty, Ital. Heart J. (November 22);3(11): pp. 676 681. 24. Guven H, Thanigaraj S, Beardslee M, Noninvasive evaluation of a cutting balloon entrapped in a left main coronary artery using transesophageal echocardiography, Echocardiography (February 25);22(2): pp. 133 135. 52